Generate Investment Management Ltd Cuts Position in Stryker Corporation $SYK

Generate Investment Management Ltd lessened its position in Stryker Corporation (NYSE:SYK) by 55.0% during the first quarter, Holdings Channel reports. The fund owned 13,917 shares of the medical technology company’s stock after selling 17,005 shares during the period. Generate Investment Management Ltd’s holdings in Stryker were worth $4,573,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in SYK. Godfrey Financial Associates Inc. bought a new position in shares of Stryker during the 4th quarter valued at about $26,000. Sankala Group LLC bought a new stake in Stryker in the 4th quarter worth approximately $26,000. United Financial Planning Group LLC purchased a new stake in Stryker in the third quarter worth approximately $27,000. Atlas Capital Advisors Inc. purchased a new stake in Stryker in the fourth quarter worth approximately $27,000. Finally, DJE Kapital AG bought a new position in Stryker during the fourth quarter valued at approximately $28,000. Institutional investors own 77.09% of the company’s stock.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP M Kathryn Fink sold 3,500 shares of Stryker stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the transaction, the vice president owned 177 shares of the company’s stock, valued at $50,170.65. The trade was a 95.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 323,264 shares of company stock valued at $100,659,489 in the last three months. 4.60% of the stock is currently owned by company insiders.

Stryker Stock Performance

Shares of SYK stock opened at $304.64 on Tuesday. The company has a market capitalization of $116.79 billion, a P/E ratio of 35.26, a PEG ratio of 1.97 and a beta of 0.78. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The stock has a 50 day moving average price of $313.12 and a two-hundred day moving average price of $341.06.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the prior year, the business posted $2.84 EPS. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts expect that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is 40.74%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Canaccord Genuity Group lowered their price objective on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. Needham & Company LLC reduced their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a research report on Friday, May 1st. Wells Fargo & Company lowered their price target on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Finally, Weiss Ratings lowered shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $395.33.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.